The era of male birth control is approaching
For nearly a half-century, Sujoy Guha has worked to perfect a male contraceptive. Now the 86-year-old Indian doctor’s idea is gaining momentum, raising the prospect of changing the way birth control is practiced across the globe.
For decades, Sujoy Guha, an 86-year-old Indian doctor, has been working on a male contraceptive. His injectable solution, known as RISUG, temporarily blocks sperm from passing through the vas deferens, the tubes that carry sperm from the testicles. The technology, however, has encountered numerous challenges, including regulatory hurdles and bureaucratic obstacles, and remains under development in India.
In the United States, companies are racing to develop their own versions of male contraceptives, known as "vas-occlusive" contraceptives. One such company is Next Life Sciences, which is developing Plan A, a nonhormonal contraceptive that uses Vasalgel and is designed to last about 10 years. The contraceptive can be reversed with a second injection of sodium bicarbonate solution, dissolving the gel.
Next Life Sciences' founder, L.R. Fox, emphasizes the convenience of the contraceptive, stating that users do not have to worry about daily compliance. The interest in male contraception has been described as "explosive," with 55,000 men on the company's interest list, and one Plan A video has garnered 4.5 million views overnight.
Another company, Contraline, is developing ADAM, another nonhormonal hydrogel contraceptive that also blocks sperm passage through the vas deferens. The procedure is initially designed to degrade on its own over two years. Kevin Eisenfrats, co-founder and CEO of Contraline, is optimistic about the broadscale adoption of reversible male contraception, highlighting the importance of men being able to provide and afford the contraceptive.
ADAM is currently in its first human study, a proof of concept aimed at assessing safety and feasibility before a larger efficacy study for regulatory approval. The company recently received $92.5 million in financing, with the majority going towards the development of its hormonal contraceptive arm.
Currently, men have only two widely available contraceptive options: condoms and vasectomies. Women, on the other hand, have over a dozen contraceptive methods, many of which come with side effects. A 2024 KFF survey found that 82% of reproductive-age women had used contraception in the prior 12 months, and among contraceptive users who would prefer an alternative method, 23% would prefer that their partner get a vasectomy.
The documentary "Give It a Shot" sheds light on the long-running effort to bring a reversible male contraceptive to market, examining why responsibility for birth control has fallen so heavily on women. The film explores the potential for men to take a more active role in contraception, potentially contributing to greater gender equity.
Written by urgent.news from IOL's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.